other material
confidence high
sentiment positive
materiality 0.75
Skye Bioscience Q3: Nimacimab + semaglutide shows 29% greater weight loss vs semaglutide alone; net loss $12.8M
Skye Bioscience, Inc.
- Nimacimab plus semaglutide achieved 29% relative increase in weight loss vs semaglutide alone at 26 weeks; clean safety profile.
- Combination reduced waist circumference by 3.2 cm (1.25 inches) vs semaglutide alone.
- Rebound weight gain was 18.1% vs 49.8% for semaglutide alone over 12 weeks post-treatment.
- Q3 2025 net loss of $12.8M; cash $35.3M; runway into 2027.
- Extension study fully enrolled (43 patients); data expected Q1 2026.